Bishal Gyawali
@oncology_bgPersonal acc. Med Onc. A/Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNySfB Talks- https://t.co/anav3AJx9m
Similar User
@DrHBurstein
@JCO_ASCO
@Annals_Oncology
@FAndreMD
@btfoundation
@matteolambe
@JAMAOnc
@SidYadavMD
@OncoAlert
@FDAOncology
@E_de_Azambuja
@ASCOPres
@ErikaHamilton9
@CharuAggarwalMD
@neerajaiims
One of the most important #globaloncology #cancerpolicy studies our group has published. esmoopen.com/article/S2059-… We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit…
🌟 We’re thrilled to announce Dr. Bishal Gyawali (Canada) as a speaker at the Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer Conference, taking place online from December 6-8, 2024! Dr. Gyawali will be presenting on a thought-provoking and essential…
Ian Tannock reminds us how "informed censoring" can artificially bias a PFS curve to mislead the @FDAOncology to approve a new cancer drug when it doesn't work, and instead HARMS patients. @csoncol @oncology_bg medbio.utoronto.ca/faculty/tannock
I’m entering hospice today. Will probably update every little if at all. But I wanted to say to be kind, be brave, be principled, be an idealist. Most importantly, be a decent human. I love that we existed together, in this moment of time.
Have you been checking out the Skills Lab videos at @MedscapeOnc ? In these videos, I provide insights on how to read a clinical trial report. search.medscape.com/search/?q=skil…
Look who is coming to @QueensUHealth Oncology Grand Rounds this Thursday! This is sure to be a fascinating talk. The Moral Economy of Cancer Drug Development.
This is sad. It’s like a hammer seeing nails everywhere. Just because you have ozempic doesn’t mean everything is obesity. We even have a mnemonic in medicine for distended abdomen- the 6 F’s- fluid, fat, feces, flatus, fetus, or fatal tumors (cancers). nypost.com/2024/11/04/lif…
Surrogate endpoints under scrutiny in oncology! 🧬 Common Sense Oncology challenges the use of endpoints like PFS in drug approvals, calling for better patient-centered measures. Dr. Bishal Gyawali breaks it down. bit.ly/3BO8Lc7 #DrugPrices @csoncol @oncology_bg
This is just “genius” @VPrasadMDMPH @AaronGoodman33
Queridos colegas en la industria: este tipos de discusiones con nosotros son las que realmente son relevantes. No den por sentado que todos sabemos claramente que beneficios o no tienen los medicamentos. No solo es buscar una venta: es buscar genuinamente beneficiar al px.
Great study! I'm intrigued by the benchmark for meaningful benefit and justified prices in LMICs. $120/month for PFS drugs and $360/month for OS drugs seems like a valuable starting point for discussion. #Cancer #ESMO #OncoDaily #Oncology
What oncologists and cancer patients perceive as meaningful benefit or justified prices - @oncology_bg @HealthCommunic2 @SirohiBhawna oncodaily.com/blog/180891 #Cancer #ESMO #OncoDaily #Oncology #MedEd #MedX #MedNews #Medicine
👇🏻Really interesting paper - look fwd to further work looking at patient perspective
One of the most important #globaloncology #cancerpolicy studies our group has published. esmoopen.com/article/S2059-… We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit…
OS gold standard but do we place too much time on quantitative rather than qualitative benefits in time? If something truly improved quality of life then that would often trump both PFS and OS. Why the right thing for many patients is stopping and having good palliative care
Very “real world” responses and practical answers. Love it
The best part of our new study is the quotes. The quotes give you a picture of the ground reality. For example, these quotes on response rates. esmoopen.com/article/S2059-…
Interesting for so many reasons: Violations of homo-economicus abound!
One of the most important #globaloncology #cancerpolicy studies our group has published. esmoopen.com/article/S2059-… We talk a lot about "meaningful benefit" or "appropriate prices" of cancer drugs, but there is no data on what oncologists and patients perceive as meaningful benefit…
A new #globaloncology #cancerpolicy study, co-authored by @queensu's Bishal Gyawali, reveals oncologists’ perceptions on endpoints, benefit, price, and value of cancer drugs: bit.ly/4fkrLho @oncology_bg @QueensGlobalOnc
United States Trends
- 1. Tyson 498 B posts
- 2. $MAYO 13,2 B posts
- 3. #wompwomp 6.062 posts
- 4. Syracuse 17,5 B posts
- 5. Pence 60,6 B posts
- 6. Paige 6.722 posts
- 7. Kiyan 20,7 B posts
- 8. Kash 102 B posts
- 9. The FBI 265 B posts
- 10. Debbie 34,2 B posts
- 11. Iron Mike 21,5 B posts
- 12. Whoopi 112 B posts
- 13. #LetsBONK 15,5 B posts
- 14. Shu Shu 27,5 B posts
- 15. Dora 24,7 B posts
- 16. Mike Rogers 20,7 B posts
- 17. Connor Williams 1.488 posts
- 18. Ronaldo 197 B posts
- 19. Karoline Leavitt 4.119 posts
- 20. Gabrielle Union 2.304 posts
Who to follow
-
Harold J. Burstein, MD, PhD, FASCO
@DrHBurstein -
Journal of Clinical Oncology
@JCO_ASCO -
Annals of Oncology
@Annals_Oncology -
FabriceAndre
@FAndreMD -
Binaytara Foundation
@btfoundation -
Matteo Lambertini, MD PhD
@matteolambe -
JAMA Oncology
@JAMAOnc -
Sid Yadav MD, FACP
@SidYadavMD -
OncoAlert
@OncoAlert -
FDA Oncology
@FDAOncology -
Evandro de Azambuja, MD, PhD
@E_de_Azambuja -
Robin Zon, MD, FACP, FASCO
@ASCOPres -
Erika Hamilton, MD
@ErikaHamilton9 -
Charu Aggarwal, MD, MPH, FASCO
@CharuAggarwalMD -
Neeraj Agarwal, MD, FASCO
@neerajaiims
Something went wrong.
Something went wrong.